United States of America v. Miraca Life Sciences, Inc.

CourtDistrict Court, M.D. Tennessee
DecidedSeptember 24, 2024
Docket3:13-cv-01025
StatusUnknown

This text of United States of America v. Miraca Life Sciences, Inc. (United States of America v. Miraca Life Sciences, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States of America v. Miraca Life Sciences, Inc., (M.D. Tenn. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

UNITED STATES OF AMERICA ex rel. ) PAUL DORSA, ) ) Plaintiff, ) NO. 3:13-cv-01025 ) v. ) JUDGE CAMPBELL ) MAGISTRATE JUDGE FRENSLEY MIRACA LIFE SCIENCES, INC., ) ) Defendant. )

MEMORANDUM

Relator Paul Dorsa brought this action on behalf of himself and in the name of the United States of America alleging violations of the False Claims Act (“FCA”), 31 U.S.C. § 3729 et seq. by Defendant Miraca Life Sciences, Inc. (“Miraca”). The claims in this matter have been resolved by settlement, except for Dorsa’s claim that he was fired in retaliation for efforts to stop activity that he believed was in violation of the FCA. (See Doc. Nos. 59, 87). Now before the Court is Miraca’s motion for summary judgment on the retaliation claim, which is fully briefed. (Doc. Nos. 190, 191, 200, 202). In support of the motion, Miraca filed a Statement of Undisputed Material Facts (Doc. No. 192), to which Dorsa responded (Doc. Nos. 201).1 Among the evidence Dorsa put forth in response to Miraca’s motion for summary judgment is the Expert Report of Lorene Schaefer, Esq. (Doc. No. 199-11), which Miraca has moved to exclude (Doc. No. 206). Dorsa also filed two notices of supplemental authority (Doc. Nos. 221, 227).

1 For ease of reference, Miraca’s Statement of Undisputed Material Facts (Doc. No. 192), together with Dorsa’s Response (Doc. No. 201) is cited as “Miraca SUMF ¶__.” Also before the Court is Dorsa’s Motion for Review of Non-Dispositive Order of Magistrate Judge seeking review of the Magistrate Judge’s privilege rulings. (Doc. No. 215). An Order on the Motion for Review has been entered separately. For the reasons explained in that Order, the Court concludes Miraca has waived privilege as to certain documents. However,

because these documents do not affect the ultimate disposition of the motion for summary judgment, the Court need not delay decision on the instant motion. For the reasons stated herein, Miraca’s motion for summary judgment (Doc. No. 190) will be denied and Miraca’s Motion to Exclude Lorene Schaefer’s Expert Report and Testimony (Doc. No. 206) will be denied as moot. I. BACKGROUND During the relevant time period, Miraca was a diagnostics services company that provided “pathology services” in various healthcare specialties. Paul Dorsa began working for Miraca in July or August 2012 as Senior Vice President of Commercial Operations. (Miraca SUMF ¶ 7). Dorsa was in charge of Miraca’s sales team. (Id. ¶ 8). Dr. Frank Basile was Miraca’s Chief

Executive Officer, Russell Farr was General Counsel, and John Rasmussen was Assistant General Counsel and Chief Compliance Officer.2 (Id. ¶¶ 4-6). At the time, a “safe-harbor” to the Anti-Kickback Statute allowed companies to make donations to physicians to implement electronic health records in physicians’ offices. 42 C.F.R. § 1001.952(y) to the Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)). The safe-harbor was subject

2 The parties rely extensively on the deposition testimony of Dorsa, Basile, Rasmussen, and Farr. For ease of reference these depositions are cited as “Dorsa Dep.,” “Basile Dep.,” “Rasmussen Dep.,” and “Farr Dep.” Their depositions are filed in the record as follows: Dorsa Dep. (Doc. Nos 193, Ex.6, and 199- 2); Basile Dep. (Doc. Nos. 193, Ex. 1, and 199-5); Rasmussen Dep. (Doc. No. 193, Ex. 2, and 199-8); Farr Dep. (Doc. No. 193, Ex. 3, and 199-3).

2 to limitations on the value of the donation and required that the physician receiving the donation could not make the donation a “condition of doing business with the donor,” and the donor could not “directly take into account the volume or value of referrals … generated between the parties in determining whether to donate or the amount of the donation.” 42 C.F.R. § 1001.952(y)(4)-(6)

(2013); 42 C.F.R. § 411.357(w)(5)-(7) (2013). Miraca had a process to approve donations that required Dorsa, Basile, and others to execute a form authorizing the donation (the “Donation Form”). (Miraca SUMF ¶ 13). Dorsa came to believe that Miraca’s donations did not fall within the safe-harbor and, therefore, violated the Anti-Kickback Statute. (Dorsa Dep. at 112, 127, 147; Dorsa Decl., Doc. No. 199-4 at ¶ 7). Dorsa never sent these concerns in writing to Miraca, but he claims to have shared them with Basile, Farr, and Rasmussen from September 2012 through August 2013.3 (Dorsa Dep. at 120, 125, 210-211, 299-303). Dorsa testified that he had a standing weekly meeting with Basile and that he raised these concerns with Basile on numerous other occasions. (Id. at 207). Although he could not recall the specific dates of these other conversations, Dorsa testified that he told Basile

that “our practice was different than our policy and different than the agreement that Mintz had put together … And that it was a violation of the False Claims Act and that we were going to have issues.” (Id. at 210-11). Dorsa said he also reported to Basile that an analyst told Dorsa that “he’s got file boxes filled with files that will put us in jail.” (Id. at 211). Dorsa says after he reported this to Basile, Basile told Rasmussen and the boxes were shipped to Phoenix. (Id.). Plaintiff stated that he does not remember with specificity each and every conversation he had with Basile and Farr

3 Dorsa said he did not submit anything about his concerns in writing because he worked with “these gentlemen” everyday and “to put it in writing would have implied that I was setting up for a lawsuit.” (Dorsa Dep., Doc. No. 199-2 at 197). Dorsa said that he was focused on trying to correct the problem and that it “was never [his] intention to file the qui tam.” (Id.).

3 about the EMR donation program during this time period or the precise words he used during those conversations, but he generally recalls “making it clear to Mr. Basile and Mr. Farr that making donations to induce referrals violated the Anti-Kickback Statute, tainted the referrals Miraca received, and resulted in fraud on the Government, which was obvious to Plaintiff and others at

Miraca given the company’s substantial volume of Medicare business.” (Pl. Response to Interrogatory No. 3, Doc. No. 193-1 at PageID# 2361). Dorsa also stated that he had separate conversations with Basile and Farr regarding a letter Miraca received in July 2013 from a law firm representing Rahway Pathology, which alleged that Miraca had violated various state and federal laws by offering EMR donations to obtain referrals. (Id. at PageID# 2362). Referring to the contents of the letter, Dorsa told Basile and Farr, “this is what I’ve been saying is the problem.” (Id.). In June and July 2013, at the direction of his attorneys, Dorsa drafted multiple versions of a letter to Farr, but he never sent a letter to Miraca. (Miraca SUMF ¶ 34 (citing Plaintiff’s Privilege Log and Dorsa Dep. at 230-35)). Dorsa testified he did not feel a “sense of urgency” to send the

letter because he “constantly talked with him about what was in – what was in the letter.” (Dorsa Dep. at 233-34). In August 2013, Dorsa decided he would no longer sign the Donation Forms. (Id. at 15, 99, 141, 197, 208, 235-36). He told Basile that he would not sign the Donation Forms because of “the compliance problem of fraud and abuse,” “anti-kickback” violations, and “False Claims Act” violations associated with the company’s donation program.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Pram Nguyen v. City of Cleveland
229 F.3d 559 (Sixth Circuit, 2000)
Donald G. Wexler v. White's Fine Furniture, Inc.
317 F.3d 564 (Sixth Circuit, 2003)
Richard M. Yuhasz v. Brush Wellman, Inc.
341 F.3d 559 (Sixth Circuit, 2003)
Carolyn T. Rodgers v. Elizabeth Banks
344 F.3d 587 (Sixth Circuit, 2003)
Nicole Burton v. Freescale Semiconductor, Inc., et
798 F.3d 222 (Fifth Circuit, 2015)
Bible Believers v. Wayne County
805 F.3d 228 (Sixth Circuit, 2015)
Cynthia Miles v. S. Central Human Resource Agency
946 F.3d 883 (Sixth Circuit, 2020)
Chris Davis v. James Gallagher
951 F.3d 743 (Sixth Circuit, 2020)
John George v. Youngstown State Univ.
966 F.3d 446 (Sixth Circuit, 2020)
Lee Briggs v. Univ. of Cincinnati
11 F.4th 498 (Sixth Circuit, 2021)
Cicero v. Borg-Warner Automotive, Inc.
280 F.3d 579 (Sixth Circuit, 2002)
Jones-McNamara v. Holzer Health Systems
630 F. App'x 394 (Sixth Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
United States of America v. Miraca Life Sciences, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-v-miraca-life-sciences-inc-tnmd-2024.